26 de mayo de 2019
  • Sábado, 25 de Mayo
  • Viernes, 24 de Mayo
  • 2 de marzo de 2010

    Archimedes Pharma Announces Major Fund Raising of GBP65 Million (y 2)

    Archimedes' technologies - ChiSys(R), PecSys(TM) and TARGIT(R) - are also used in a number of partnered products in late-stage clinical development. ChiSys, an innovative drug delivery technology which enhances the residence time of molecules on mucosal membranes, has proven potential for vaccine delivery. Pre-clinical and clinical studies of nasally administered vaccines have demonstrated enhanced immune response. PecSys(TM) is Archimedes' patented drug delivery system built around its novel pectin technology, designed to maximise the potential of systemically absorbed drugs by enhancing drug performance and improving patient acceptance.

    For more information, please visit: http://www.archimedespharma.com.

    Jeffrey H. Buchalter

    Jeffrey H. Buchalter has over 20 years experience in the pharmaceutical industry. He was previously President and CEO of Enzon Pharmaceutical Inc. since 2004 and also served as Chairman of the Board of Directors until May 2009. Prior to this, Jeffrey was President and CEO of ILEX Oncology, Inc. where he led the company's transformation from a drug development contract research organization to a product-driven pharmaceutical company. Before joining ILEX Oncology Inc., Jeffrey held key roles at Pharmacia, Wyeth (formerly American Home Products) and Schering-Plough Corporation.

    Jeffrey received the American Cancer Society's Joseph F. Buckley Memorial Award and an invitation from former President George Bush to serve as a collaborating partner in the National Dialogue on Cancer. Jeffrey was recently appointed Chairman to the Board of Trustees of The National Children's' Cancer Foundation (NCCF); he is also a member of the Board of Directors of TopoTarget A/S, a publicly held Danish biopharmaceutical company.

    Jeffrey has a B.S. in finance from Seton Hall University, and an M.B.A. in marketing from Temple University.

    About Warburg Pincus

    Warburg Pincus is a leading global private equity firm. The firm has more than $30 billion in assets under management. Its active portfolio of more than 100 companies is highly diversified by stage, sector and geography. Warburg Pincus is a growth investor and an experienced partner to management teams seeking to build durable companies with sustainable value. Founded in 1966, Warburg Pincus has raised 12 private equity funds which have invested more than $35 billion in approximately 600 companies in more than 30 countries. Since the firm's first European transaction in 1983, Warburg Pincus has invested more than $6 billion in European companies, including investments in Archimedes, Eurand and ProStrakan. Additional life science investments include Allos Therapeutics, Ganic Pharmaceuticals, InterMune, Rib-X Pharmaceuticals and ZymoGenetics. The firm has offices in Beijing, Frankfurt, Hong Kong, London, Mumbai, New York, San Francisco, Shanghai and Tokyo. For more information, please visit http://www.warburgpincus.com.

    About Novo A/S and Novo Growth Equity

    Novo A/S is the holding and investment company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. Novo A/S was formed in 1999 to actively manage the assets of the foundation. It employs about 30 people and has approximately USD 15 billion of assets under management. These includes significant shareholdings in the publicly listed Novo Nordisk A/S (NYSE: NVO) and Novozymes A/S (NVZMF.PK), Novo A/S provides seed, venture and growth capital to development stage companies within life science and biotechnology, as well as manages a broad portfolio of financial assets. Novo A/S is committing up to USD 300 million annually to its investments in seed, venture and growth equity life science companies. Of this, nearly two-thirds are directed to the Novo Growth Equity activities focusing on investment in promising late stage companies with near term commercial potential. For further information please visit http://www.novo.dk.

    For further information, please contact:

    Capital MS&L:

    Mary Clark, Supriya Mathur, Tel: +44(0)20-7307-5347

    For further information, please contact: Capital MS&L: Mary Clark, Supriya Mathur, Tel: +44(0)20-7307-5347